Status: Not yet recruiting
RE-irradiation of Diffuse MIdline Glioma paTients
The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.
Participants needed: 59
Trial details
Age: 12-21Biological sex: AllType: InterventionalSponsor: Rigshospitalet, DenmarkUpdated: Oct 23, 2023
Eligibility criteria
Diffuse midline glioma diagnosis: verified radiologically or histologically Biop... [+8]
Presence of leptomeningeal spread or multifocal disease on MRI at progression [+4]